The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Eli Lilly shares rise 2.6% as investors rotate toward blockbuster diabetes and weight-loss drugs
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 18, 3:15 PM EDT

Eli Lilly shares rise 2.6% as investors rotate toward blockbuster diabetes and weight-loss drugs

The move comes as traders weigh demand momentum behind Mounjaro and Zepbound, while a separate valuation snapshot suggests the stock may trade below an estimated fair value.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly’s shares jumped about 2.6% in market trading on Aug. 18, according to a Yahoo Finance report, as investors appeared to rotate away from “expensive tech” and toward more defensive or cash-flow visible healthcare exposure.

The report attributes the stock gain to continued strength in Lilly’s major injectable products for metabolic disease, specifically Mounjaro and Zepbound. It says these therapies are fueling “record growth,” indicating that Lilly’s growth narrative remains anchored on the demand cycle for its diabetes and weight-loss franchise.

Mounjaro is a brand of tirzepatide, an injectable medicine used for type 2 diabetes. Zepbound is also based on tirzepatide and is used for weight management. Together, the two products sit at the center of Lilly’s current earnings outlook because they address two of the largest commercial markets in modern pharma: diabetes management and obesity treatment.

In addition to citing product momentum, the Yahoo post references a GuruFocus valuation view that places Lilly shares below an “estimated fair value.” GuruFocus is not a regulator and does not set market prices, but the mention underscores that at least some market participants are looking for upside if fundamentals continue to beat expectations.

Still, the Yahoo Finance item does not provide the underlying figures that would typically accompany claims of record growth, such as quarterly revenue, unit prescriptions, pricing or pharmacy inventory trends. It also does not outline any new regulatory action, trial result, reimbursement update, or guidance change from Lilly in connection with the move.

Without those specifics, investors’ immediate takeaway is more about sentiment than new disclosure. The report frames the rise as a response to ongoing demand for Mounjaro and Zepbound and a valuation argument that the stock could be trading at a discount relative to an internal estimate of fair value.

More broadly, the “rotation” framing matters because it highlights how cross-sector flows can lift pharma even when there is no company-specific headline. If markets remain concerned about valuation levels in growth stocks, healthcare companies with sustained product demand can attract relative inflows, particularly when their key assets are already established in routine clinical use.

Why It Matters

  • Lilly’s near-term market performance appears tied to investor confidence in continued strength for its tirzepatide franchise in both diabetes and weight management.
  • Sentiment driven by positioning toward or away from “expensive tech” suggests broader risk and valuation factors are influencing healthcare stock moves.
  • Valuation comparisons to “estimated fair value” can support tactical buying when investors believe fundamentals are outpacing expectations.
  • However, without disclosed numbers or new company updates in the cited post, it may be difficult to distinguish fresh catalysts from normal market repricing.

Sources

Key Facts

  • Eli Lilly shares rose about 2.6% in trading on Aug. 18, per a Yahoo Finance report.
  • The report links the move to demand momentum for Mounjaro and Zepbound.
  • The report describes Mounjaro and Zepbound as fueling “record growth,” without providing detailed figures in the post.
  • The Yahoo item also cites a GuruFocus view that Lilly shares trade below an estimated fair value.
  • No new Lilly disclosure or guidance change is described in the Yahoo report text provided for this prompt.

Healthcare Related

Eli Lilly shares rise 2.6% as investors rotate toward blockbuster diabetes and weight-loss drugs | The Apex Times